Neuroplast, a Dutch clinical-stage biotech, focusing on cell-based treatments for neurodegenerative diseases, has Injury (TSCI). Preliminary data indicate an excellent safety profile due to the complete absence of product related adverse events. Furthermore, patient feedback confirms excellent tolerability. The trial is conducted in collaboration with Hospital Nacional de Parapléjicos in Toledo, Spain, and Rigshospitalet in […]
Successful patient inclusion of Phase II clinical trial for Traumatic Spinal Cord Injury
